相关临床试验
28
24 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
24
85.7%
已完成
1
3.6%
招募中
3
10.7%
暂无批准数据
- The Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) market was valued at approximately $750 million in 2022 and is expected to grow significantly through 2034, driven by increasing disease prevalence and emerging therapies. - aTyr Pharma continues enrollment in its Phase 2 EFZO-CONNECT study evaluating efzofitimod for SSc-ILD, with participants receiving either 270mg, 450mg, or placebo administered intravenously over six monthly doses. - Several promising candidates in the pipeline, including PRA023, Belimumab, and Vixarelimab, are poised to reshape the treatment landscape for SSc-ILD, addressing significant unmet needs in this serious pulmonary complication.
- Merck's Winrevair, combined with background therapy, significantly improved outcomes in patients with severe pulmonary arterial hypertension (PAH). - The ZENITH trial was halted early due to Winrevair's overwhelming efficacy compared to placebo in reducing mortality and disease-related hospitalization. - Winrevair, acquired through the Acceleron acquisition, is projected to reach peak sales of $5 billion annually, driven by its impact on PAH treatment. - The drug's success in the ZENITH trial may broaden its application, pending further data and regulatory review.
• Merck & Co. announced plans to pursue biotechnology acquisitions up to $15 billion as it prepares for its blockbuster cancer drug Keytruda to lose patent protection in 2028. • The company's recent strategic moves include an $11 billion Acceleron acquisition, a $10.8 billion Prometheus Biosciences takeover, and a potential $22 billion cancer drug deal with Daiichi Sankyo. • Merck is developing a subcutaneous version of Keytruda and projects its pipeline of cancer, immune, and cardiac disease drugs to generate over $35 billion in sales by mid-next decade.
